Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA6 | P23280 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429787 | 0.89 | HSD17B10 (0.52) | HSD17B10PTGS2CA2CA4CA1 | |
| SCHEMBL14154475 | 0.87 | PTGS2 (0.50) | PTGS2CA2CA4GAATAAR1 | |
| SCHEMBL3993269 | 0.86 | ALDH1A1 (0.40) | HSD17B10PTGS2GAANCOA1NCOA3 | |
| SCHEMBL14211626 | 0.81 | HSD17B10 (0.38) | HSD17B10CA2CA4GAACA1 | |
| SCHEMBL12325395 | 0.80 | PTGS2 (0.44) | PTGS2CA2TAAR1CA1DHFR | |
| SCHEMBL10600312 | 0.79 | MAPT (0.50) | HSD17B10CA2CA4GAACA1 | |
| SCHEMBL2945602 | 0.78 | ALDH1A1 (0.48) | HSD17B10PTGS2TAAR1MAPT | |
| SCHEMBL12885657 | 0.78 | ACHE (0.48) | HSD17B10PTGS2TAAR1DHFRMAPT | |
| SCHEMBL21547605 | 0.78 | PTGS2 (0.60) | PTGS2GAATAAR1DHFRMAPT | |
| SCHEMBL12101787 | 0.77 | GABRA1 (0.40) | GABRA1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
| US-6451845-B1 | ANTIDIABETIC AGENTS | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| CN-1308625-A | Naphtho [2, 3-B ] heteroar-4-yl derivatives | AMERICAN HOME PROD (US) | 2001-08-15 | — | — | CN | disclosed |
| US-6248764-B1 | ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-19 | — | — | US | disclosed |
| EP-1077968-A1 | NAPHTHO[2,3-B]HETEROAR-4-YL DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6121271-A | ANTIDIABETIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| US-6103708-A | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| WO-1999058522-A1 | NAPHTHO[2,3-B]HETEROAR-4-YL DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | HSD17B10 400/4885PTGS2 3783/4885CA2 1382/4885 |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, FFAR3 | HSD17B10 375/4885PTGS2 3518/4885CA2 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.